Preclinical Evaluation of the Breast Cancer Cell-Binding Peptide, P160

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-05-0432
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Preclinical Evaluation of a GFRA1 Targeted Antibody-Drug Conjugate in Breast Cancer

Oncotarget
Oncology
2018English

P160 RhoA-binding Kinase ROKα Induces Neurite Retraction

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1998English

Development of JNK2-Selective Peptide Inhibitors That Inhibit Breast Cancer Cell Migration

ACS Chemical Biology
BiochemistryMedicineMolecular Medicine
2011English

Preclinical and Clinical Effects of Mistletoe Against Breast Cancer

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2014English

Preclinical Evaluation of a Novel Triple-Acting PIM/PI3K/mTOR Inhibitor, IBL-302, in Breast Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2020English

Evaluation of Synthetic Isoflavones on Cell Proliferation, Estrogen Receptor Binding Affinity, and Apoptosis in Human Breast Cancer Cells

Journal of Steroid Biochemistry and Molecular Biology
Molecular MedicineCell BiologyMolecular BiologyBiochemistryEndocrinologyClinical BiochemistryMetabolismDiabetes
2008English

Immunotherapeutic Strategies in Breast Cancer: Preclinical and Clinical Trials

2007English

A Systematic Approach to Preclinical Trials in Metastatic Breast Cancer

Chemotherapy: Open Access
2016English

gH625 Cell-Penetrating Peptide Promotes the Endosomal Escape of Nanovectorized siRNA in a Triple-Negative Breast Cancer Cell Line

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy